FASENRA PEN
As listed in the register: FASENRA PEN
30 mg · solution
- Prescription only
- Breathing, airways, allergies and cough
- Active substance
- Benralizumab
- Made by
- Astrazeneca Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (FASENRA). It describes the substance, not this exact product.
Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with a dissociation constant of 11 pM.
The IL-5 receptor is expressed on the surface of eosinophils and basophils.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-05-13
Safety of the active substance
From the US prescribing label for the same active substance (FASENRA). It describes the substance, not this exact product.
- FASENRA is contraindicated in patients who have known hypersensitivity to benralizumab or any of its excipients [see Warnings and Precautions (5.1) ].
- Known hypersensitivity to benralizumab or excipients.
Most common adverse reactions (incidence greater than or equal to 5%):.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Astrazeneca Canada Inc |
|---|---|
| Active substance | Benralizumab |
| Used in | Breathing, airways, allergies and cough |
| Strength | 30 mg |
| Form | solution |
| Classification | R03DX10 · Breathing, airways, allergies and cough |
| Route | subcutaneous |
| Dispensing (as stated by the register) | PRESCRIPTION · SCHEDULE D |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02496135 |
| DPD drug code | 98601 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.